Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abeyance, adenosine, Analgesic, Anesthetic, antagonist, AQ, Arcoxia, Asmanex, ASR, Avelox, back, breast, Cerazette, Clarinex, Claritin, conceded, concomitant, Coppertone, Council, Cozaar, CRL, daily, desloratadine, dispute, documented, dosage, Dulera, elderly, ertapenem, essentially, etoricoxib, Ezetrol, flat, Follistim, follitropin, Fosamac, Fosavance, Francisco, Gardasil, Glynn, Goldman, golimumab, hypersensitivity, Hyzaar, Implanon, Inegy, inspection, interpretation, intolerant, introduce, Invanz, Jellema, Liptruzet, Maxalt, Ministry, Munter, nonproprietary, outlined, Oxytrol, Parkinson, Pedrojetti, PegIntron, Phleum, preempted, preladenant, Primaxin, ProQuad, Proscar, Puregon, recognition, recombinant, recoverable, Remeron, Remicade, remit, render, resident, Rosenberg, RotaTeq, salt, San, Scheinberg, Scholl, secondary, Sessner, Singulair, Spano, spent, sponte, statue, Su, sua, suspend, Sycrest, Temodal, Trusopt, Twisthaler, Unanski, undiscounted, unknown, Utah, Varivax, Wisconsin, Young, Zessin, Zocor, Zostavax
Removed:
admissibility, agentHyzaar, andCoppertonesun, andFosamax, andHyzaar, andResearch, andVytorin, asAeriusin, asEzetrol, asFosamacin, asFosavance, Asia, asInegy, asOther, asPuregon, asTemodal, beende, blinded, bothRemicadeandSimponi, bothZetiaandZocor, building, butsua, byNuvaRing, captionIn, cell, Central, certainFosamaxproduct, chemotherapy, commercializeSimponi, Controlled, favorably, firstFosamaxONJ, forCosopt, forCozaarandHyzaarin, forDulera, forSimponi, forSingulair, forSingulairexpired, forSycrest, FosamaxLitigation, fromAOCI, inAccrued, inAccumulated, inactivated, inAOCIuntil, inCozaar, inEquity, inNoncontrolling, inOther, inPedrojetti, inRestructuring, inRosenberg, inSessner, involvingPropecia, lead, manufactureNuvaRing, marketRemicade, marketRemicadeto, mix, nameSycrest, NuvaRingMDL, ofBridion, ofClarinex, ofCozaar, ofEmend, ofFollistim, ofFosamax, ofFosamaxand, ofGardasil, ofJanumet, ofJanuvia, ofMaxalt, ofNasonex, ofNuvaRing, ofProQuad, ofSimponi, ofSimponiin, ofSingulair, ofTemodar, ofVarivax, ofVioxx, ofVioxxseeking, ofVytorin, ofZetia, ofZostavax, onVioxxby, orOther, orVytorin, Pacific, partial, pneumococcal, polyvalent, prescriptionClaritin, presenting, recommended, region, remainingVioxxProduct, role, selectedScheinberg, sponteordered, Substance, successful, testimony, thebolescase, theCarrie, theFosamax, thefosamaxonj, theNasonex, theNuvaRing, theNuvaRingMDL, thevioxx, theVioxxProduct, theVytorin, throughOther, toIncome, toSalesmay, toSimponi, toSycrest, toVioxx, toVioxxin, underwriter, withinOCI, withinResearch
Filing tables
Filing exhibits
Related press release
MRK similar filings
Filing view
External links